Business · 08/01/2021Updated: 10/17/2026 · 1 min read
FDA Reopens Comment Period for 503B Bulks List Notice
Summary
The FDA is reopening the comment period for a notice regarding the 503B Bulks List, which identifies bulk drug substances with clinical need, following a request from interested persons for additional time to submit comments.